GC BIOSCIENCE
DEAD

Serial Number

97298596

Owner

Green Cross Holdings Corporation

Attorney

Kwang Yup Chae

Filing Date

Mar 7, 2022

Add to watchlist:

No watchlists yet
View on USPTO

GC BIOSCIENCE Trademark

Serial Number: 97298596

GC BIOSCIENCE is a trademark filed by Green Cross Holdings Corporation on March 7, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Green Cross Holdings Corporation (24 trademarks)

107, Ihyeon-ro 30beon-gil, Giheung-gu,
Yongin-si, Gyeonggi-do 16924 , KR

Entity Type: 03

Trademark Details

Filing Date

March 7, 2022

Registration Date

Not Registered

Published for Opposition

December 13, 2022

Goods & Services

Medicines for humans used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; Medicines for humans, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors; Medicated plasters; Vaccines; Biological preparations for medical or veterinary purposes, namely, biological preparations used for the prevention and treatment of cancer, cerebrovascular thrombosis, myocardial infarctions, peripheral artery occlusions, pulmonary embolisms, thrombocytopenia, thrombophlebitis, Japanese Encephalitis, Hepatitis B Virus, Hepatitis C Virus, Immunodeficiency disease, Human Immunodeficiency Virus, rare disease, Hunter Syndrome, Hemophilia, Hemophilia A, arthritis, osteoarthritis, arthritis deformans, periarthritis humeroscapularis, tendinitis, peritendinitis, humeral epicondylitis, idiopathic thrombocytopenic purpura, Guillain-barre syndrome, Kawasaki syndrome, Clostridium tetani, virus infection, influenza, bacterial infection and chronic pain; Biological preparations for medical or veterinary purposes, namely, blood plasma-derivatives, namely, albumins, immunoglobulins, and blood clotting factors; Dietary and nutritional supplements

Wholesale distributorships and retail store services featuring pharmaceutical products; Export and import agencies in the field of pharmaceutical products; Wholesale store services featuring biological preparations for medical purposes; Retail store services featuring biological preparations for medical purposes; Retail store services featuring pharmaceutical preparations for the treatment of cells; Retail store services featuring medical instruments; Retail store services featuring medical apparatus; Retail store services featuring medical genetic analyzer; Retail store services featuring electromedical diagnostic instruments; Wholesale store services featuring pharmaceutical preparations for the treatment of cells; Wholesale store services featuring medical instruments; Wholesale store services featuring medical apparatus; Wholesale store services featuring medical genetic analyzer; Wholesale store services featuring electromedical diagnostic instruments; all the foregoing excluding services in the field of industrial, institutional, commercial and janitorial equipment and supplies; Financial intermediary services, namely, facilitating the channeling of funds between lenders and borrowers by connecting those with a financial surplus with those having a financial deficit in the field of pharmaceutical products and medical equipment; Operation of a business for others, namely, wholesale distributorships and retail stores featuring pharmaceutical products; Procurement, namely, purchasing pharmaceutical products for other businesses

Research and development of vaccines and medicines; Research and development, laboratory and scientific research in the field of pharmaceuticals, blood plasma preparations, recombinant proteins and antibodies; Conducting clinical studies of medicines for medical research purposes; Clinical research in the nature of performing biopsies for medical research; Product research and development of medical products; Conducting technical project studies, namely, engineering services in the nature of technical project planning and design engineering of medical products; Testing, inspection or research of pharmaceuticals; Scientific research relating to biology; Scientific research in the field of genetic engineering; Research and development of technology for biotechnology; Scientific research in the fields of biomedicine; Laboratory research in the field of biology; Product development of cell therapy products; Drug discovery services; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of gene analysis; Medical studies, namely, medical laboratory services; Research and development of technology for medicinal chemical manufacturing; Medical research services relating to clinical data

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 16, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 16, 2026 ABN6
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 16, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 16, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 28, 2025 EXRA
SOU EXTENSION 5 GRANTED
Nov 28, 2025 EX5G
SOU EXTENSION 5 FILED
Jul 2, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Jul 2, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jan 10, 2025 EX4G
SOU EXTENSION 4 FILED
Jan 10, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 10, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 25, 2024 EXRA
SOU EXTENSION 3 GRANTED
Jun 25, 2024 EX3G
SOU EXTENSION 3 FILED
Jun 25, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 25, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 7, 2024 EXRA
SOU EXTENSION 2 GRANTED
Feb 5, 2024 EX2G
SOU EXTENSION 2 FILED
Feb 5, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 5, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 14, 2023 EXRA
SOU EXTENSION 1 GRANTED
Mar 10, 2023 EX1G
SOU EXTENSION 1 FILED
Mar 10, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 10, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 7, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 13, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 13, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 23, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 4, 2022 CNSA
EXAMINERS AMENDMENT -WRITTEN
Nov 4, 2022 CNEA
EXAMINER'S AMENDMENT ENTERED
Nov 4, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 4, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 4, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 4, 2022 CNEA
EXAMINER'S AMENDMENT ENTERED
Nov 4, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 4, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 4, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 4, 2022 CNEA
ASSIGNED TO EXAMINER
Oct 28, 2022 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Mar 12, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 11, 2022 NWOS
NEW APPLICATION ENTERED
Mar 10, 2022 NWAP